Literature DB >> 30727754

Osteopontin in Vascular Disease.

Zoe Shin Yee Lok1, Alicia N Lyle2.   

Abstract

Inflammatory cytokines are necessary for an acute response to injury and the progressive healing process. However, when this acute response does not resolve and becomes chronic, the same proteins that once promoted healing then contribute to chronic inflammatory pathologies, such as atherosclerosis. OPN (Osteopontin) is a secreted matricellular cytokine that signals through integrin and CD44 receptors, is highly upregulated in acute and chronic inflammatory settings, and has been implicated in physiological and pathophysiologic processes. Evidence from the literature suggests that OPN may fit within the Goldilocks paradigm with respect to cardiovascular disease, where acute increases are protective, attenuate vascular calcification, and promote postischemic neovascularization. In contrast, chronic increases in OPN are clinically associated with an increased risk for a major adverse cardiovascular event, and OPN expression is a strong predictor of cardiovascular disease independent of traditional risk factors. With the recent finding that humans express multiple OPN isoforms as the result of alternative splicing and that these isoforms have distinct biologic functions, future studies are required to determine what OPN isoform(s) are expressed in the setting of vascular disease and what role each of these isoforms plays in vascular disease progression. This review aims to discuss our current understanding of the role(s) of OPN in vascular disease pathologies using evidence from in vitro, animal, and clinical studies. Where possible, we discuss what is known about OPN isoform expression and our understanding of OPN isoform contributions to cardiovascular disease pathologies.

Entities:  

Keywords:  atherosclerosis; cytokines; inflammation; osteopontin; risk factors; vascular diseases

Mesh:

Substances:

Year:  2019        PMID: 30727754      PMCID: PMC6436981          DOI: 10.1161/ATVBAHA.118.311577

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  119 in total

1.  Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury.

Authors:  Julie L Chan; Thomas M Reeves; Linda L Phillips
Journal:  Exp Neurol       Date:  2014-08-21       Impact factor: 5.330

2.  CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis.

Authors:  Y U Katagiri; J Sleeman; H Fujii; P Herrlich; H Hotta; K Tanaka; S Chikuma; H Yagita; K Okumura; M Murakami; I Saiki; A F Chambers; T Uede
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

Review 3.  Osteopontin as a Potential Therapeutic Target for Ischemic Stroke.

Authors:  Qiquan Zhu; Xu Luo; Jie Zhang; Yun Liu; Hansheng Luo; Qin Huang; Yuan Cheng; Zongyi Xie
Journal:  Curr Drug Deliv       Date:  2017-09-06       Impact factor: 2.565

4.  C-terminal modification of osteopontin inhibits interaction with the αVβ3-integrin.

Authors:  Brian Christensen; Eva Kläning; Mette S Nielsen; Mikkel H Andersen; Esben S Sørensen
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

5.  Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile.

Authors:  I Barchetta; C Alessandri; L Bertoccini; F A Cimini; L Taverniti; M Di Franco; A Fraioli; M G Baroni; M G Cavallo
Journal:  Eur J Endocrinol       Date:  2015-11-17       Impact factor: 6.664

6.  Cross-linking of osteopontin by tissue transglutaminase increases its collagen binding properties.

Authors:  M T Kaartinen; A Pirhonen; A Linnala-Kankkunen; P H Mäenpää
Journal:  J Biol Chem       Date:  1999-01-15       Impact factor: 5.157

7.  Osteopontin plays an important role in the development of medial thickening and neointimal formation.

Authors:  Kikuo Isoda; Kenichirou Nishikawa; Yashuhiro Kamezawa; Mikoto Yoshida; Masatoshi Kusuhara; Masao Moroi; Norihiro Tada; Fumitaka Ohsuzu
Journal:  Circ Res       Date:  2002-07-12       Impact factor: 17.367

8.  Secreted kinase phosphorylates extracellular proteins that regulate biomineralization.

Authors:  Vincent S Tagliabracci; James L Engel; Jianzhong Wen; Sandra E Wiley; Carolyn A Worby; Lisa N Kinch; Junyu Xiao; Nick V Grishin; Jack E Dixon
Journal:  Science       Date:  2012-05-10       Impact factor: 47.728

9.  The role of osteopontin in inflammatory processes.

Authors:  Susan Amanda Lund; Cecilia M Giachelli; Marta Scatena
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

10.  Matricellular proteins: an overview.

Authors:  Paul Bornstein
Journal:  J Cell Commun Signal       Date:  2009-09-25       Impact factor: 5.782

View more
  44 in total

Review 1.  An update on vascular calcification and potential therapeutics.

Authors:  Anubha Singh; Simran Tandon; Chanderdeep Tandon
Journal:  Mol Biol Rep       Date:  2021-01-04       Impact factor: 2.316

Review 2.  Interactive and Multifactorial Mechanisms of Calcific Vascular and Valvular Disease.

Authors:  Linda L Demer; Yin Tintut
Journal:  Trends Endocrinol Metab       Date:  2019-07-03       Impact factor: 12.015

3.  Silencing METTL3 Stabilizes Atherosclerotic Plaques by Regulating the Phenotypic Transformation of Vascular Smooth Muscle Cells via the miR-375-3p/PDK1 Axis.

Authors:  Jingquan Chen; Kun Lai; Xi Yong; Hongshun Yin; Zhilong Chen; Haifei Wang; Kai Chen; Jianghua Zheng
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-15       Impact factor: 3.727

4.  Osteopontin promotes infarct repair.

Authors:  Itai Rotem; Tal Konfino; Tal Caller; Yeshai Schary; Olga Shaihov-Teper; Dahlia Palevski; Nir Lewis; Daria Lendengolts; Nili Naftali-Shani; Jonathan Leor
Journal:  Basic Res Cardiol       Date:  2022-10-14       Impact factor: 12.416

Review 5.  Cardiovascular disease in systemic lupus erythematosus.

Authors:  Maureen McMahon; Richard Seto; Brian J Skaggs
Journal:  Rheumatol Immunol Res       Date:  2021-12-15

6.  Circulating and tissue matricellular RNA and protein expression in calcific aortic valve disease.

Authors:  Alexander P Kossar; Wanda Anselmo; Juan B Grau; Yichuan Liu; Aeron Small; Samuel L Carter; Lisa Salvador; Lei Zhao; Mary Ellen Cvijic; Zhuyin Li; Melissa Yarde; Nancy Rioux; Daniel J Rader; Robert J Levy; Giovanni Ferrari
Journal:  Physiol Genomics       Date:  2020-02-24       Impact factor: 3.107

7.  miR-33 Silencing Reprograms the Immune Cell Landscape in Atherosclerotic Plaques.

Authors:  Milessa Silva Afonso; Monika Sharma; Martin Schlegel; Coen van Solingen; Graeme J Koelwyn; Lianne C Shanley; Lauren Beckett; Daniel Peled; Karishma Rahman; Chiara Giannarelli; Huilin Li; Emily J Brown; Alireza Khodadadi-Jamayran; Edward A Fisher; Kathryn J Moore
Journal:  Circ Res       Date:  2021-02-17       Impact factor: 17.367

8.  Osteopontin and osteoprotegerin in atherosclerotic plaque - are they significant markers of plaque vulnerability?

Authors:  Cristina Strobescu-Ciobanu; Simona Eliza Giuşcă; Irina Draga Căruntu; Cornelia Amălinei; Andreea Rusu; Elena Cojocaru; Radu Florin Popa; Cristian Dumitru Lupaşcu
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

9.  Single-Cell RNA Sequencing Reveals Heterogeneity of Vascular Cells in Early Stage Murine Abdominal Aortic Aneurysm-Brief Report.

Authors:  Huan Yang; Ting Zhou; Amelia Stranz; Elise DeRoo; Bo Liu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-01-21       Impact factor: 8.311

10.  Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus.

Authors:  Lina Wirestam; Muna Saleh; Christina Svensson; Michele Compagno; Helene Zachrisson; Jonas Wetterö; Christopher Sjöwall
Journal:  Lupus       Date:  2021-05-06       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.